Navigation Links
AbbVie Issues Inaugural Full-Year Outlook for 2013
Date:1/30/2013

and the advancement of key development programs, including the start of Phase III studies for our interferon-free Hepatitis C (HCV) combination and elagolix.

AbbVie expects long-term growth will be fueled by a compelling pipeline of therapies in development to address medical conditions with high unmet need.  The company is focused on advancing a number of Phase III programs, including: an interferon-free oral combination for HCV; daclizumab for relapsing remitting multiple sclerosis (in partnership with Biogen); elagolix for endometriosis; elotuzumab for multiple myeloma (in partnership with Bristol Myers Squibb); and several new indications for HUMIRA.

In 2013, the company expects to initiate several Phase III programs including atrasentan for diabetic kidney disease and ABT-199 in chronic lymphocytic leukemia (CLL).  Additionally, AbbVie is planning Phase IIB starts for: elagolix in uterine fibroids; our partnered JAK1 inhibitor (GLPG0634) for rheumatoid arthritis (RA); BT-061 for RA; and ABT-719 for acute kidney injury associated with major cardiac and other surgeries.  Finally, in 2013, the company intends to present data from a number of key development programs, including our rapidly advancing HCV program, oncology, renal disease, immunology and Alzheimer's disease.

Management to Discuss Company Performance and Outlook on Investor Call TodayAbbVie will host an investor conference call today at 8 a.m. Central time to discuss our fourth-quarter and full-year 2012 highlights and 2013 outlook. Participating on the call will be Rick Gonzalez , chairman and chief executive officer; Bill Chase , executive vice president and chief financial officer; Laura Schumacher , executive vice president of business development, external affairs and general counsel; John Leonard , senior vice president and chief scientific o
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AbbVie Named to S&P 500 Dividend Aristocrat Index
2. Emmaus Life Sciences Issues Statement in Response to Announcement by AFH Holding & Advisory
3. Qualitest Issues Voluntary, Nationwide Recall of 101 Lots of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/500 mg Due to the Potential for Oversized Tablets
4. Fero Industries, Inc. Issues Corporate Update
5. CSL Behring Parent Company, CSL Limited, Issues Fourth Corporate Responsibility Report
6. Ranbaxy Issues Voluntary Nationwide Recall of 41 lots of Atorvastatin Calcium Tablets 10 mg, 20 mg and 40 mg Due to Potential Presence of Foreign Substance
7. Emmaus CEO Yutaka Niihara, M.D., Issues Statement In Connection with Status of Companys Phase III FDA Sickle Cell Treatment Trials
8. Zi Xiu Tang Success, LLC Issues Voluntary Nationwide Recall of Classic Zi Xiu Tang Bee Pollen Capsules and Ultimate Formula Capsules due to Undeclared Sibutramine
9. CORRECTION: Star Scientific Issues Statement Correcting the Underreporting of the "Flint" CRP Human Study Results
10. Qualitest Issues Voluntary, Nationwide Recall for One Lot of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/500 mg Due to the Potential for Oversized Tablets
11. Sun Pharmaceutical Industries, Inc. Issues Nationwide Voluntary Recall of One Lot of Nimodipine Capsules due to Crystallization of the Fill Material
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... DALLAS , December 24, 2014 /PRNewswire/ ... Research Report on Global Disposable Syringe Industry ... to its online business intelligence library. ... Global Disposable Syringe Industry is a professional ... Syringe market.  For overview analysis, the report ...
(Date:12/24/2014)... 2014   Assurex Health, a personalized medicine ... providers for behavioral health and chronic pain conditions, ... in equity financing from new and existing investors, ... and Chief Executive Officer. The financing ... Assurex Health,s GeneSight ®  products.  GeneSight,s ...
(Date:12/24/2014)... , Dec. 23, 2014  The American Diabetes ... pressure target for people with diabetes and that ... high doses of statins, in keeping with recent ... by the American College of Cardiology (ACC) and ... in the most recent changes to the Association,s ...
Breaking Medicine Technology:World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4
... Warner Chilcott plc (Nasdaq: WCRX ) announced today ... Inc. ("Par").  The Paragraph IV Certification Notice advises the Company of the ... generic version of the Company,s ASACOL 400 mg delayed release mesalamine product. ... ASACOL 400 mg, which ...
... RATON, Fla. , June 28 ... launch Anastrozole 1mg Tablets.  The U.S. Food and Drug Administration ... (ANDA) for this first time generic, which is being supplied ... Arimidex®, a billion dollar cancer drug marketed by AstraZeneca.  Breckenridge ...
Cached Medicine Technology:Warner Chilcott Announces Receipt of Paragraph IV Certification Notice 2Warner Chilcott Announces Receipt of Paragraph IV Certification Notice 3
(Date:12/25/2014)... 26, 2014 Recently, Dylan Queen, a ... excitedly released its collection of discounted prom dresses, most ... a senior spokesman of the company, the promotion is ... promotion is to expand the UK market. , The ... different colors, lengths, and styles: A-line strapless, empire strapless ...
(Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International ... after an 8 year battle with breast cancer. ... in her home in Woodland Hills California after an ... , As the founder and volunteer President ... and championed many of today's greatest breakthroughs in restoring ...
(Date:12/25/2014)... The risk of burns from fires and cooking accidents ... extra cautious, an expert says. "Between Thanksgiving and ... patients coming in with burns," said Dr. Steven Sandoval, ... Center of Stony Brook University Hospital in New York. ... if not careful, could quickly turn tragic," Sandoval said ...
(Date:12/25/2014)... tries its best to translate the experience of dress ... introduced its new collection of 2015 prom dresses, and ... prom outfits are guaranteed to contain the perfect designs ... designed for 2015. Anyone who wants to buy ... before Jan. 26, 2015, the deadline of the promotion. ...
(Date:12/25/2014)... December 25, 2014 Residents at ... Community, recently showed their generous spirit by providing ... Catawba County Parenting Network- Grandparents Raising Grandchildren program. ... gathered around the largest Christmas tree on the ... purchased by residents of the Abernethy Village Association ...
Breaking Medicine News(10 mins):Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Don't Let Burns Mar Your Holidays 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Retirement Community Residents Make Impact During Holiday Season 2
... of Dollars, GENEVA, SWITZERLAND, Feb. 11 ... will begin negotiations,here on an historic international treaty ... massive global problem that undermines efforts to reduce,tobacco ... and terrorist,organizations, and costs governments billions in revenue., ...
... LONDON, February 11 , - New Solution ... Efficiency, Misys plc (FTSE: MSY.L), the global ... in Pakistan has gone live with Misys,Equation. The ... revenues,reduce risk and drive business efficiency through processing, ...
... 11 MedThink Communications, an,innovator in medical ... been retained by Salix Pharmaceuticals, Inc, in,Morrisville ... under development, an,orally disintegrating form of metoclopramide., ... market the orally disintegrating,metoclopramide tablet and will ...
... Technology Into its ... ... the developer of,Software Lens(TM) technology, today announced a strategic cooperation ... integrates,Dblur,s Software Lens(TM) technology into STMicroelectronics, sensor and,camera module products., ...
... of Web pages dedicated to disseminating breast cancer information, ... Houston have determined that while most breast cancer data ... Web pages featured inaccuracies and sites displaying complementary and ... false or misleading health information. , Published in ...
... rest of the cells in your body, your red blood ... when mammals began to evolve. Other vertebrates such as fish, ... are inactive. Losing the nucleus enables the red blood cell ... be transported in the blood and boosting our metabolism. ...
Cached Medicine News:Health News:Nations to Launch Negotiations on Treaty to Combat Illicit Tobacco Trade 2Health News:Nations to Launch Negotiations on Treaty to Combat Illicit Tobacco Trade 3Health News:Nations to Launch Negotiations on Treaty to Combat Illicit Tobacco Trade 4Health News:Mybank Goes Live With Misys Equation to Support Rapid Growth and Meet Future Regulatory Requirements 2Health News:MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product 2Health News:MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product 3Health News:Dblur Concludes Licensing Deal With STMicroelectronics 2Health News:Review of online breast cancer information encourages healthy skepticism for consumers 2Health News:How red blood cells nuke their nuclei 2
Overall length 355 mm, 14.0 inches....
Achievement, available exclusively from Art Optical, is a unique RGP lens design with a patented junctionless back surface and a controlled edge lift....
... of the Polycon II lens design with ... The result is a thin lens that ... surface characteristics, durability and superior oxygen delivery. ... service and expedited delivery, Artcon is the ...
Boston Multivision design is manufactured in Boston ES material for early presbyope patients. Boston Multivision lens provides crisp, clear vision at near, intermediate, and far distances and excelle...
Medicine Products: